- Home
- ROIV vs DLTR Comparison
ROIV vs DLTR Comparison
Compare ROIV & DLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | DLTR |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 20.9B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ROIV | DLTR |
|---|---|---|
| Price | $28.12 | $107.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 18 |
| Target Price | $27.56 | ★ $123.94 |
| AVG Volume (30 Days) | ★ 4.5M | 2.7M |
| Earning Date | 02-06-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 144.33 |
| EPS | N/A | ★ 6.22 |
| Revenue | $29,053,000.00 | ★ $19,411,800,000.00 |
| Revenue This Year | N/A | $8.51 |
| Revenue Next Year | $594.84 | $6.00 |
| P/E Ratio | ★ N/A | $17.42 |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $8.73 | $68.86 |
| 52 Week High | $30.33 | $142.40 |
Technical Indicators
Market Signals| Indicator | ROIV | DLTR |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 42.00 |
| Support Level | $26.94 | $97.71 |
| Resistance Level | $30.33 | $116.14 |
| Average True Range (ATR) | 0.95 | 3.81 |
| MACD | -0.12 | 0.58 |
| Stochastic Oscillator | 79.20 | 38.69 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DLTR Dollar Tree Inc.
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2024, Dollar Tree generated over $17 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.